Relapsed hydroxychloroquine induced thrombocytopenia in a systemic lupus erythematosus patient
Reumatol Clin. 2017 Sep-Oct;13(5):294-296.
doi: 10.1016/j.reuma.2016.04.008.
Epub 2016 Jun 2.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Medicina Interna, Hospital Moisès Broggi, Sant Joan Despí Barcelona, Barcelona, España. Electronic address: vanesa.anton.v@gmail.com.
- 2 Servicio de Medicina Interna, Hospital Moisès Broggi, Sant Joan Despí Barcelona, Barcelona, España.
- 3 Servicio de Reumatología, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, España.
- 4 Servicio de Nefrología, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, España.
Abstract
Hydroxychloroquine is used in the long-term therapy of systemic lupus erythematosus (SLE). Although considered to be a safe treatment, side effects have been documented. An uncommon side effect is thrombocytopenia. In order to establish the diagnosis of thrombocytopenia secondary to Hydroxychloroquine, non-pharmacological causes must be ruled out and it is necessary to determine a recurrence after re-exposure to the drug. We present one case of severe thrombocytopenia occurring in a patient with SLE undergoing treatment with Hydroxychloroquine.
Keywords:
Hidroxicloroquina; Hydroxychloroquine; Lupus eritematoso sistémico; Systemic lupus erythematosus; Thrombocytopenia; Trombocitopenia.
Copyright © 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
MeSH terms
-
Adult
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use
-
Humans
-
Hydroxychloroquine / adverse effects*
-
Hydroxychloroquine / therapeutic use
-
Lupus Erythematosus, Systemic / complications
-
Lupus Erythematosus, Systemic / drug therapy*
-
Male
-
Recurrence
-
Thrombocytopenia / chemically induced*
-
Thrombocytopenia / diagnosis
Substances
-
Antirheumatic Agents
-
Hydroxychloroquine